人脑恶性胶质瘤生物治疗的临床研究

Clinical Study of Biotherapy in Patient with Malignant Glioma of the Brain

报告27例人脑胶质瘤生物治疗的临床结果，LAK细胞／IL－2治疗组12例，其中复发性星形细胞瘤10例，丘脑胶质瘤2例，有效率为33％。TIL／IL－2治疗组15例，星形细胞瘤及少枝胶质瘤均为术后肿瘤残留着，分别为12例和3例，有效率为47％。二组总有效率为40％。临床研究结果表明LAK细胞及TIL／IL-2是治疗人脑胶质瘤安全、有一定疗效的新途径。

This study involves clinical results of 27 cases of brain malignant glioma, which is divided into two groups.The first involves 12 cases of LAK/IL-2 treated group among which 10 are recurrent astrocytoma, 2 are thalamus glioma. Of them, 2 have CR (complete response), 2 have PR (partial response), 3 wjth MR (minor response) and 5 with NR (no response), the therapeutic effectiveness reaches 33%. Another group involves 15 cases with treatment of TIL/IL- 2. Among them 12 cases bear with post-operative remnants of atyocytoma and 3 with residual oligedendroglioma, and their results are 3 cases of CR, 4 of PR, 6 or MR and 2 of NR, the clinic effectiveness reaches 40%. These clinical research findings point out that LAK cell and TIL/IL-2 treatment are effective comprehensive medical treatment with biological implement.